 |
| |
|
SWI Ratings Report Adds Three BioTechs
|
|
|
Marina del Rey, CA - June 2, 2016 - StockWatchIndex today added three new biotech companies to its "QuickPicks" Ratings Report. We believe that the recent low in the sector has created excellent mid and long-term investment opportunities for innovative biotechs.
Our QuickPicks ratings report is a collection of the consolidated opinions of our StockWatchIndex research team and other credible third party researches. The information in this newsletter is meant to serve as crucial information for the short term investor, who may want to be
seeking faster returns. We typically do not hold positions in any of these stocks at the time of publishing, but always consider investing moving forward.
For both, our SWI Portfolio and the SWI QuickPicks, we provide frequent performance reports to support our subscribers' investment decisions and keep track of our performance.
|
|
|
|
|
Mesoblast Limited engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore.
|
|
|
|
|
|
|
Athersys, Inc. focuses on research and development in the field of regenerative medicine. The company's MultiStem cell therapy for the treatment of ischemic stroke and inflammatory bowel disease is in Phase II clinical trials.
|
|
|
|
|
|
|
Summit Therapeutics (SMMT)
|
|
Summit Therapeutics focuses on the discovery, development, and commercialization of medicines to treat genetic and infectious diseases in the United Kingdom and North America
|
|
|
|
|
Go to the individual company websites for more detailed information
|
|
|
Please visit our sites www.stockwatchindex.com and www.swiresearch.com and our Strategic Partner site www.smallcapnation.com. We would appreciate if you could pass our newsletter on to your friends and colleagues. We always appreciate your feedback and suggestions for improvements.
If you are interested in a research report for your public company, or want us to consider your top pick, please contact us at [email protected].
|
|
|
Rainer Poertner - Chief Analyst
|
|
|
StockWatchIndex and SWI Research (SWI) are not registered investment advisers and the information provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI has not been compensated
for the publication of the information herein
. The included information is subject to change without notice. Please visit
www.swiresearch.com/#!legal-ease/lmvw1
for a full text of our Disclaimer, Privacy policy and Terms of Use.
|
|
|
|
|
|
|
|
